First Time Loading...

MorphoSys AG
XETRA:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
XETRA:MOR
Watchlist
Price: 67.7 EUR -0.07% Market Closed
Updated: Apr 23, 2024

Intrinsic Value

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. [ Read More ]

The intrinsic value of one MOR stock under the Base Case scenario is 27.56 EUR. Compared to the current market price of 67.7 EUR, MorphoSys AG is Overvalued by 59%.

Key Points:
MOR Intrinsic Value
Base Case
27.56 EUR
Overvaluation 59%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
MorphoSys AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MOR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
MorphoSys AG

Provide an overview of the primary business activities
of MorphoSys AG.

What unique competitive advantages
does MorphoSys AG hold over its rivals?

What risks and challenges
does MorphoSys AG face in the near future?

Summarize the latest earnings call
of MorphoSys AG.

What significant events have occurred
in MorphoSys AG over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for MorphoSys AG.

Provide P/S
for MorphoSys AG.

Provide P/E
for MorphoSys AG.

Provide P/OCF
for MorphoSys AG.

Provide P/FCFE
for MorphoSys AG.

Provide P/B
for MorphoSys AG.

Provide EV/S
for MorphoSys AG.

Provide EV/GP
for MorphoSys AG.

Provide EV/EBITDA
for MorphoSys AG.

Provide EV/EBIT
for MorphoSys AG.

Provide EV/OCF
for MorphoSys AG.

Provide EV/FCFF
for MorphoSys AG.

Provide EV/IC
for MorphoSys AG.

Show me price targets
for MorphoSys AG made by professional analysts.

What are the Revenue projections
for MorphoSys AG?

How accurate were the past Revenue estimates
for MorphoSys AG?

What are the Net Income projections
for MorphoSys AG?

How accurate were the past Net Income estimates
for MorphoSys AG?

What are the EPS projections
for MorphoSys AG?

How accurate were the past EPS estimates
for MorphoSys AG?

What are the EBIT projections
for MorphoSys AG?

How accurate were the past EBIT estimates
for MorphoSys AG?

Compare the revenue forecasts
for MorphoSys AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of MorphoSys AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of MorphoSys AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of MorphoSys AG compared to its peers.

Compare the P/E ratios
of MorphoSys AG against its peers.

Discuss the investment returns and shareholder value creation
comparing MorphoSys AG with its peers.

Analyze the financial leverage
of MorphoSys AG compared to its main competitors.

Show all profitability ratios
for MorphoSys AG.

Provide ROE
for MorphoSys AG.

Provide ROA
for MorphoSys AG.

Provide ROIC
for MorphoSys AG.

Provide ROCE
for MorphoSys AG.

Provide Gross Margin
for MorphoSys AG.

Provide Operating Margin
for MorphoSys AG.

Provide Net Margin
for MorphoSys AG.

Provide FCF Margin
for MorphoSys AG.

Show all solvency ratios
for MorphoSys AG.

Provide D/E Ratio
for MorphoSys AG.

Provide D/A Ratio
for MorphoSys AG.

Provide Interest Coverage Ratio
for MorphoSys AG.

Provide Altman Z-Score Ratio
for MorphoSys AG.

Provide Quick Ratio
for MorphoSys AG.

Provide Current Ratio
for MorphoSys AG.

Provide Cash Ratio
for MorphoSys AG.

What is the historical Revenue growth
over the last 5 years for MorphoSys AG?

What is the historical Net Income growth
over the last 5 years for MorphoSys AG?

What is the current Free Cash Flow
of MorphoSys AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for MorphoSys AG.

Financials

Balance Sheet Decomposition
MorphoSys AG

Current Assets 814m
Cash & Short-Term Investments 682.8m
Receivables 38.9m
Other Current Assets 92.4m
Non-Current Assets 1.2B
Long-Term Investments 3.6m
PP&E 15m
Intangibles 1.2B
Other Non-Current Assets 7.3m
Current Liabilities 264.3m
Accounts Payable 109.8m
Other Current Liabilities 154.5m
Non-Current Liabilities 1.7B
Long-Term Debt 252.8m
Other Non-Current Liabilities 1.5B
Efficiency

Earnings Waterfall
MorphoSys AG

Revenue
238.3m EUR
Cost of Revenue
-51m EUR
Gross Profit
187.3m EUR
Operating Expenses
-420.2m EUR
Operating Income
-232.9m EUR
Other Expenses
43.2m EUR
Net Income
-189.7m EUR

Free Cash Flow Analysis
MorphoSys AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MOR Profitability Score
Profitability Due Diligence

MorphoSys AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
ROIC is Increasing
Exceptional Revenue Growth Forecast
40/100
Profitability
Score

MorphoSys AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

MOR Solvency Score
Solvency Due Diligence

MorphoSys AG's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
31/100
Solvency
Score

MorphoSys AG's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MOR Price Targets Summary
MorphoSys AG

Wall Street analysts forecast MOR stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MOR is 57.12 EUR with a low forecast of 17.17 EUR and a high forecast of 71.4 EUR.

Lowest
Price Target
17.17 EUR
75% Downside
Average
Price Target
57.12 EUR
16% Downside
Highest
Price Target
71.4 EUR
5% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

MOR Price
MorphoSys AG

1M 1M
+1%
6M 6M
+162%
1Y 1Y
+244%
3Y 3Y
-10%
5Y 5Y
-23%
10Y 10Y
+7%
Annual Price Range
67.7
52w Low
16.085
52w High
67.95
Price Metrics
Average Annual Return -26.38%
Standard Deviation of Annual Returns 50.4%
Max Drawdown -91%
Shares Statistics
Market Capitalization 2.5B EUR
Shares Outstanding 37 594 501
Percentage of Shares Shorted
N/A

MOR Return Decomposition
Main factors of price return

What is price return decomposition?

MOR News

Other Videos

Last Important Events
MorphoSys AG

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
MorphoSys AG

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

MorphoSys AG Logo
MorphoSys AG

Country

Germany

Industry

Biotechnology

Market Cap

2.5B EUR

Dividend Yield

0%

Description

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. The company is headquartered in Planegg, Bayern and currently employs 648 full-time employees. The firm develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The firm's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The firm develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.

Contact

BAYERN
Planegg
Semmelweisstr. 7
+4989899270.0
https://www.morphosys.com

IPO

1999-03-09

Employees

648

Officers

Chairman of Management Board, MD & CEO
Dr. Jean-Paul Kress M.D.
CFO & Member of Management Board
Dr. Lucinda Crabtree Ph.D.
Chief Legal and Human Resources Officer & Member of Management Board
Ms. Charlotte Lohmann
Head of Accounting & Tax
Mr. Klaus De Wall
Head of Discovery Alliances & Technologies
Dr. Margit Urban
Head of Investor Relations
Dr. Julia Neugebauer Ph.D.
Show More
Chief Business Officer
Dr. Barbara Krebs-Pohl Ph.D.
Head of Technical Operations
Dr. GĂĽnter Wellnhofer
Head of Alliance Management
Dr. Harald Watzka
Head of Clinical Operations
Ms. Yen Ching Chua
Show Less

See Also

Discover More
What is the Intrinsic Value of one MOR stock?

The intrinsic value of one MOR stock under the Base Case scenario is 27.56 EUR.

Is MOR stock undervalued or overvalued?

Compared to the current market price of 67.7 EUR, MorphoSys AG is Overvalued by 59%.